Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis.
Pediatric pulmonology
, Feb. 2012: 125-134
Association of intraventricular hemorrhage secondary to prematurity with cerebrospinal fluid shunt surgery in the first year following initial shunt placement.
Journal of Neurosurgery. Pediatrics
, Jan. 2012: 54-63
Risk of Post Lung Transplant Renal Dysfunction in Adults with Cystic Fibrosis.
Chest
, Jan. 2012
Risk factors for chronic kidney disease in adults with cystic fibrosis.
American journal of respiratory and critical care medicine
, Nov. 2011: 1147-52
Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.
Archives of pediatrics & adolescent medicine
, Sept. 2011: 847-56
Treatment and microbiology of repeated cerebrospinal fluid shunt infections in children.
The Pediatric infectious disease journal
, Sept. 2011: 731-5
Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis.
Journal of clinical microbiology
, July 2011: 2772-3
Using bacterial biomarkers to identify early indicators of cystic fibrosis pulmonary exacerbation onset.
Expert review of molecular diagnostics
, March 2011: 197-206
Open-label, Follow-On Study to Assess Continued Efficacy and Safety of Azithromycin in Children and Adolescents with CF Uninfected with Pseudomonas aeruginosa.
Pediatric Pulmonology (In press)
, 2011
Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation.
The New England journal of medicine
, Nov. 2010: 1991-2003
An international randomized multicenter comparison of nasal potential difference techniques.
Chest
, Oct. 2010: 919-28
Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.
JAMA : the journal of the American Medical Association
, May 2010: 1707-15
A pipeline of therapies for cystic fibrosis.
Seminars in respiratory and critical care medicine
, Oct. 2009: 611-26
Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.
Contemporary clinical trials
, May 2009: 256-68
Reproducibility of spirometry during cystic fibrosis pulmonary exacerbations.
Pediatric pulmonology
, Nov. 2008: 1142-6
Shifting patterns of inhaled antibiotic use in cystic fibrosis.
Pediatric pulmonology
, Sept. 2008: 874-81
Advancing outcome measures for the new era of drug development in cystic fibrosis.
Proceedings of the American Thoracic Society
, Aug. 2007: 370-7
Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis.
Pediatric pulmonology
, July 2007: 610-23
No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations.
American journal of respiratory cell and molecular biology
, July 2007: 57-66
Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes.
Pediatric pulmonology
, June 2007: 533-41
Laboratory parameter profiles among patients with cystic fibrosis.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
, April 2007: 117-23
Association between pulmonary function and sputum biomarkers in cystic fibrosis.
American journal of respiratory and critical care medicine
, April 2007: 822-8
Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis.
American journal of respiratory and critical care medicine
, Oct. 2005: 1008-12
Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease.
Pediatric pulmonology
, March 2005: 209-18
Improving the estimation of change from baseline in a continuous outcome measure in the clinical trial setting.
Contemporary clinical trials
, Feb. 2005: 2-16
Use of phage display to identify potential Pseudomonas aeruginosa gene products relevant to early cystic fibrosis airway infections.
Infection and immunity
, Jan. 2005: 444-52
Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis.
Thorax
, Nov. 2004: 955-9
Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial.
Chest
, Feb. 2004: 509-21
Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis.
American journal of respiratory and critical care medicine
, Dec. 2003: 1471-5
Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.
JAMA : the journal of the American Medical Association
, Oct. 2003: 1749-56
Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis.
Vaccine
, June 2003: 2448-60
Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis.
Chest
, May 2003: 1495-502
Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.
American journal of respiratory and critical care medicine
, March 2003: 841-9
The cystic fibrosis therapeutics development network (CF TDN): a paradigm of a clinical trials network for genetic and orphan diseases.
Advanced drug delivery reviews
, Dec. 2002: 1505-28
Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality.
American journal of respiratory and critical care medicine
, Dec. 2002: 1550-5
Correlation between an in vitro invasion assay and a murine model of Burkholderia cepacia lung infection.
Infection and immunity
, March 2002: 1081-6
Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center study.
Pediatric pulmonology
, Aug. 2001: 122-8
A regression modeling approach for describing patterns of HIV genetic variation.
Biometrics
, June 2001: 449-60
Revision surgeries are associated with significant increased risk of subsequent cerebrospinal fluid shunt infection
Pediatric Disease Journal (In press)
,